When the EMA announced its review, there had been 28 reports of the suicidal and self-injurious behaviour associated with semaglutide and 23 reports with liraglutide, as documented in the MHRA Yellow Card reporting scheme
Answer: Cagrilintide is used for chronic hunger and food preoccupation, plateaued progress on GLP-1 therapy, insulin resistance and prediabetes, rebound weight gain from yo-yo dieting, and body composition goals where appetite, not metabolism, is the obstacle
Alternative Names: Body Protection Compound-157, Pentadecapeptide BPC-157 BPC-157 Studies and Research Data BPC-157 Research on Wound Closure and Tissue Integrity Preclinical studies propose that BPC-157 may support wound repair by influencing fibroblast activity
If you are considering weight loss support, explore our full range of weight loss treatments and speak to a healthcare professional